Opdivo helps hold off cancer’s return in melanoma
Source: The Pharma Letter, October 2022
Bristol Myers Squibb (NYSE: BMY) has presented data that reinforces the benefits of its immuno-oncology blockbuster Opdivo (nivolumab) in the earlier stages of melanoma.
The US pharma major announced results from the Phase III CheckMate -76K trial, in which Opdivo as an adjuvant therapy demonstrated a statistically-significant and clinically-meaningful benefit in recurrence-free survival (RFS) versus placebo in completely resected stage IIB or IIC melanoma.
“Growing body of evidence supporting the clinical benefit of Opdivo for the treatment of melanoma, from the metastatic setting to earlier stages of cancer"